Canada approves Mentor's Isoloader:
This article was originally published in Clinica
Executive Summary
Mentor has gained the go-ahead in Canada to market its Isoloader system, a computerised brachytherapy workstation and automated radioactive "seed" loading system for treating prostate cancer. The system provides greater planning flexibility and improvements in radiation safety, control and documentation, while saving hours for each procedure, says Christopher Conway, Mentor's president and CEO. The Santa Barbara, California firm said that over 50,000 brachytherapy procedures were performed last year in Canada and in the US, where the product is currently under review by the FDA.